Jeff Yorio, M.D.

General Summary

Dr. Yorio is a native Texan, born and raised in Burleson near Fort Worth.  He is board certified in medical oncology, hematology, and internal medicine.  He is actively involved in clinical trial research for melanoma, head & neck cancer, renal cell carcinoma and prostate cancer with publications in the areas of melanoma, lung cancer and colorectal cancer. He strives to bring cutting edge treatments and new research to patients here in Austin.

Publications

• Fulminant Hepatic Failure After Chemosaturation With Percutaneous Hepatic Perfusion and Nivolumab in a Patient With Metastatic Uveal Melanoma

  Case Reports in Oncological Medicine, 2021

• Combined Lenvatinib and Pembrolizumab As Salvage Therapy in Advanced Adrenal Cortical Carcinoma

  Journal of Immunotherapy of Cancer, 2020

• Pembrolizumab Alone or With Chemotherapy Versus Cetuximab With Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-048): A Randomised, Open-Label, Phase 3 Study

  Lancet, 2019

• Phase 3 Study of Pembrolizumab Plus Chemoradiation (CRT) vs CRT Alone for Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

  Society for Immunotherapy of Cancer (SITC) 2017 Conference, 2017

• An Interprofessionally Developed Geriatric Oncology Curriculum for Hematology-Oncology Fellows

  Journal of Geriatric Oncology, 2015

• A Case of Vemurafenib-Induced Sweet’s Syndrome

  The Journal of Dermatology, 2014

• Treatment Decisions in a Man with Hodgkin Lymphoma and Guillian-Barre Syndrome: A Case Report

  Journal of Medical Case Reports, 2014

• Influence of Medical Comorbidities on the Presentation and Outcomes of Stage I-III Non-Small Cell Lung Cancer

  Clinical Lung Cancer, 2013

• Rare Though Not Mutually Exclusive: a Report of Three Cases of Concomitant Kras and Braf Mutation and a Review of the Literature

  Journal of Cancer, 2013

• Toxicities and Outcomes in Metastatic Melanoma Patients Treated with Ipilimumab and Braf Inhibitors

  Society for Melanoma Research 2013 Congress, 2013

• Improving the Care of Acute Lymphocytic Leukemia (ALL) at a Large County Hospital

  American Society of Clinical Oncology Quality Care Symposium, 2013

• Assessment of Absolute Lymphocyte Count (ALC) as a Predictor of Progression-Free Survival (PFS) and Overall Response Rate (ORR) in Metastatic Melanoma (MM) Patients (PTS) Treated with High-Dose Interleukin-2 (HD Il-2)

  American Society of Clinical Oncology National Meeting, 2013

• Assessment of Absolute Lymphocyte Count (ALC) as a Predictor of Progression-Free Survival (PFS) and Overall Response Rate (ORR) in Metastatic Melanoma (MM) Patients (PTS) Treated with High-Dose Interleukin-2 (HD Il-2)

  ASCO Annual Meeting, 2013

• How Have We Diagnosed Early-Stage Lung Cancer Without Radiographic Screening? A Contemporary Single-Center Experience

  PLoS ONE, 2012

• Socioeconomic Disparities in Lung Cancer Treatment and Outcomes Persist Within a Single Academic Medical Center

  Clinical Lung Cancer, 2012

• Recent Advances and Emerging Therapies in the Systemic Treatment of Metastatic Melanoma

  Clinical Oncology News, 2012

• A Primer on the Current State-of-the-Science Neoadjuvant and Adjuvant Therapy for Patients with Locally Advanced Rectal Adenocarcinomas

  International Journal of Surgical Oncology, 2012

• Presentation of Early-Stage Non-Small Cell Lung Cancer (NSCLC) Without Radiographic Screening: End of an Era?

  ASCO Annual Meeting, 2011

• The Influence of Medical Comorbidities on the Presentation and Outcome of Stage I-III Non-Small Cell Lung Cancer

  2010 ASCO Annual Meeting, 2010

• The Association Between Clinical Characteristics, Treatment Modality and Outcomes of Non-Small Cell Lung Cancer

  ASCO Annual Meeting, 2009

• The Association Between Clinical Characteristics, Treatment Modality and Outcomes of Non-Small Cell Lung Cancer

  American Society of Clinical Oncology National Meeting– Orlando, FL, 2009

• Lung Cancer Diagnostic and Treatment Intervals in the United States: A Health Care Disparity

  Journal of Thoracic Oncology, 2009

• The Effect of a Disease Management Algorithm and Dedicated Postacute Coronary Syndrome Clinic on Achievement of Guideline Compliance: Results from the Parkland Acute Coronary Event Treatment Study

  Journal of Investigative Medicine, 2008

• The Association Between Patient Characteristics, Health Care System Characteristics and Clinical Outcomes in Non-Small Cell Lung Cancer

  Eastern Cooperative Oncology Group National Meeting, 2008

• The Effect of a Disease Management Algorithm and Dedicated Post-ACS Clinic on Achievement of Guideline Compliance: Results from the Parkland Acute Coronary Event Treatment Study

  Sixth Annual University of Texas Southwestern Cardiovascular Symposium – Dallas, TX, 2006

• Increasing Use of Evidence-Based Therapies Across Ethnic Groups After Acute Coronary Events: Observations from the Parkland Acute Coronary Event Treatment Study

  Fifth Annual University of Texas Southwestern Cardiovascular Symposium – Dallas, TX, 2005